CHRS
Coherus Oncology·NASDAQ
--
--(--)
--
--(--)
Latest data update time: Updated on 2026-03-21
Latest data update time: Updated on 2026-03-21
5.20 / 10Overall Score
NeturalInvestment Rating
5.20 / 10Overall Score
NeturalInvestment Rating
Should I Buy CHRS Now?
- Based on a composite score of 5.20/10, we rate CHRS as a Netural. Our analysis breaks down into 4.39/10 for Fundamentals, 3.06/10 for Technicals, and 6.68/10 for Sentiment, indicating the stock is likely to consolidate sideways.
What is the current technical signals for CHRS?
Is CHRS fundamentally strong?
What is the market sentiment for CHRS?
Should I Buy CHRS Now?
- Based on a composite score of 5.20/10, we rate CHRS as a Netural. Our analysis breaks down into 4.39/10 for Fundamentals, 3.06/10 for Technicals, and 6.68/10 for Sentiment, indicating the stock is likely to consolidate sideways.
Is CHRS fundamentally strong?
What is the current technical signals for CHRS?
What is the market sentiment for CHRS?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
